Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
1998;275(5):G984-992
Preliminary observations from a Phase III clinical trial (NCT02896192) suggested that among 10 patients with POMC -deficient obesity (aged 6 years, BMI 30 kg/m 2 ), approximately 80% achieved a weight reduction of 10% after 1 year of treatment with setmelanotide following individualized dose titration
Tate, D
Important safety considerations include risks of pancreatitis, gallbladder disease, diabetic retinopathy progression with rapid blood glucose improvement, and dehydration from gastrointestinal side effects
Drucker, Michael A Nauck
Preclinical studies in rodents have also shown a relationship between GLP-1 RAs and the development of thyroid c-cell tumors, including medullary thyroid carcinoma (MTC)
